[19 April 2013]
Products Affected - Description
Reason for the Shortage
Greenstone and Sandoz could not provide a reason for the shortage.
Vfend tablets, Pfizer
50 mg, 30 count (NDC 00049-3170-30)
200 mg, 30 count (NDC 00049-3180-30)
Voriconazole tablets, Greenstone
50 mg, 30 count (NDC 59762-0925-01)
200 mg, 30 count (NDC 59762-0930-02)
Voriconazole tablets, Teva
50 mg, 30 count (NDC 00093-5289-56)
200 mg, 30 count (NDC 00093-5290-56)
Voriconazole tablets, Sandoz
50 mg, 30 count (NDC 00781-5667-31)
200 mg, 30 count (NDC 00781-5668-31)
Voriconazole tablets, Mylan Institutional
50 mg, 30 count unit-dose (NDC 51079-0164-03)
200 mg, 30 count unit-dose (NDC 51079-0165-03)
Voriconazole tablets, Mylan
50 mg, 30 count (NDC 00378-1626-93)
200 mg, 30 count (NDC 00378-1640-93)
Estimated Resupply Dates
All presentations are available.
April 19, 2013; March 22, 2013; February 14, 2013; January 15, 2013; December 19, 2012; December 6, 2012, University of Utah, Drug Information Service. Copyright 2013, Drug Information Service, University of Utah, Salt Lake City, UT.
This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.
« Back to Drug Shortage Product Bulletins